BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 20849361)

  • 1. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.
    Geller MA; Cooley S; Judson PL; Ghebre R; Carson LF; Argenta PA; Jonson AL; Panoskaltsis-Mortari A; Curtsinger J; McKenna D; Dusenbery K; Bliss R; Downs LS; Miller JS
    Cytotherapy; 2011 Jan; 13(1):98-107. PubMed ID: 20849361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
    Bachanova V; Cooley S; Defor TE; Verneris MR; Zhang B; McKenna DH; Curtsinger J; Panoskaltsis-Mortari A; Lewis D; Hippen K; McGlave P; Weisdorf DJ; Blazar BR; Miller JS
    Blood; 2014 Jun; 123(25):3855-63. PubMed ID: 24719405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study).
    Hoogstad-van Evert J; Bekkers R; Ottevanger N; Schaap N; Hobo W; Jansen JH; Massuger L; Dolstra H
    Medicine (Baltimore); 2019 Feb; 98(5):e14290. PubMed ID: 30702598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II trial of interleukin-15--stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors.
    Pérez-Martínez A; Fernández L; Valentín J; Martínez-Romera I; Corral MD; Ramírez M; Abad L; Santamaría S; González-Vicent M; Sirvent S; Sevilla J; Vicario JL; de Prada I; Diaz MÁ
    Cytotherapy; 2015 Nov; 17(11):1594-603. PubMed ID: 26341478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
    Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic natural killer cells for refractory lymphoma.
    Bachanova V; Burns LJ; McKenna DH; Curtsinger J; Panoskaltsis-Mortari A; Lindgren BR; Cooley S; Weisdorf D; Miller JS
    Cancer Immunol Immunother; 2010 Nov; 59(11):1739-44. PubMed ID: 20680271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.
    Szmania S; Lapteva N; Garg T; Greenway A; Lingo J; Nair B; Stone K; Woods E; Khan J; Stivers J; Panozzo S; Campana D; Bellamy WT; Robbins M; Epstein J; Yaccoby S; Waheed S; Gee A; Cottler-Fox M; Rooney C; Barlogie B; van Rhee F
    J Immunother; 2015 Jan; 38(1):24-36. PubMed ID: 25415285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
    Rubnitz JE; Inaba H; Ribeiro RC; Pounds S; Rooney B; Bell T; Pui CH; Leung W
    J Clin Oncol; 2010 Feb; 28(6):955-9. PubMed ID: 20085940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies.
    Dubois SP; Miljkovic MD; Fleisher TA; Pittaluga S; Hsu-Albert J; Bryant BR; Petrus MN; Perera LP; Müller JR; Shih JH; Waldmann TA; Conlon KC
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.
    Geller MA; Knorr DA; Hermanson DA; Pribyl L; Bendzick L; McCullar V; Miller JS; Kaufman DS
    Cytotherapy; 2013 Oct; 15(10):1297-306. PubMed ID: 23993303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors.
    Otegbeye F; Cooper B; Caimi P; Zamborsky K; Reese-Koc J; Hillian A; Hernandez-Collazo Y; Lee G; Boughan K; Tomlinson B; Gallogly M; Metheny L; Bajor D; Selfridge J; Saltzman J; Lazarus H; de Lima M; Wald D
    Transplant Cell Ther; 2022 May; 28(5):250.e1-250.e8. PubMed ID: 35172204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.
    Nguyen R; Wu H; Pounds S; Inaba H; Ribeiro RC; Cullins D; Rooney B; Bell T; Lacayo NJ; Heym K; Degar B; Schiff D; Janssen WE; Triplett B; Pui CH; Leung W; Rubnitz JE
    J Immunother Cancer; 2019 Mar; 7(1):81. PubMed ID: 30894213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.
    Shah NN; Baird K; Delbrook CP; Fleisher TA; Kohler ME; Rampertaap S; Lemberg K; Hurley CK; Kleiner DE; Merchant MS; Pittaluga S; Sabatino M; Stroncek DF; Wayne AS; Zhang H; Fry TJ; Mackall CL
    Blood; 2015 Jan; 125(5):784-92. PubMed ID: 25452614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
    Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
    Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study.
    Recchia F; Di Orio F; Candeloro G; Guerriero G; Piazze J; Rea S
    Gynecol Oncol; 2010 Feb; 116(2):202-7. PubMed ID: 19880164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
    Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
    J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
    Curti A; Ruggeri L; D'Addio A; Bontadini A; Dan E; Motta MR; Trabanelli S; Giudice V; Urbani E; Martinelli G; Paolini S; Fruet F; Isidori A; Parisi S; Bandini G; Baccarani M; Velardi A; Lemoli RM
    Blood; 2011 Sep; 118(12):3273-9. PubMed ID: 21791425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recipient lymphocyte infusion in MHC-matched bone marrow chimeras induces a limited lymphohematopoietic host-versus-graft reactivity but a significant antileukemic effect mediated by CD8+ T cells and natural killer cells.
    De Somer L; Sprangers B; Fevery S; Rutgeerts O; Lenaerts C; Boon L; Waer M; Billiau AD
    Haematologica; 2011 Mar; 96(3):424-31. PubMed ID: 21109687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.